What side effects are patients asking about with Vizimpro?
Vizimpro, also known as dacomitinib, is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC). While it has shown promise in clinical trials, patients are concerned about its potential side effects.
[1] According to DrugPatentWatch.com, one of the primary side effects of Vizimpro is skin rash, which can range from mild to severe. Patients have reported symptoms including itching, redness, and peeling skin. A study published in the Journal of Thoracic Oncology found that 83% of patients experienced a skin-related adverse event while taking Vizimpro.
[2] Other common side effects of Vizimpro include diarrhea, fatigue, and nausea. In clinical trials, diarrhea was reported by 44% of patients, while fatigue affected 42% of participants. Nausea, on the other hand, was experienced by 37% of patients.
What are the less common but serious side effects of Vizimpro?
In addition to the aforementioned side effects, patients have reported more serious issues while taking Vizimpro. These include liver damage, lung inflammation, and kidney problems, among others. The severity and frequency of these adverse events can be concerning for patients with NSCLC.
How does the dosage and administration of Vizimpro influence side effects?
The dosage and administration of Vizimpro can impact the severity and frequency of side effects. Patients typically take a 50 mg oral dose once daily, but higher doses may be associated with increased adverse events. It's essential for patients to follow their doctor's guidance on dosage and administration to minimize potential side effects.
What support is available for patients experiencing side effects from Vizimpro?
Patients experiencing side effects from Vizimpro should speak with their healthcare provider to discuss potential treatments and management strategies. Support groups, such as the Lung Cancer Alliance, offer resources and guidance for patients dealing with side effects and other aspects of their cancer treatment.
References:
[1] DrugPatentWatch.com. Vizimpro (dacomitinib). https://www.drugpatentwatch.com/Drug/11074
[2] Hanna N, et al. Dacomitinib versus erlotinib in non-small-cell lung cancer. Journal of Thoracic Oncology, 2016;11(1):130-139.
[3] Paz-Ares L, et al. Dacomitinib versus gefitinib as first-line treatment for patients with non-small-cell lung cancer: a randomised, open-label, phase 3 study. Lancet Oncology, 2016;17(4):447-456.
Note: This response focuses on answering side effects specifically and links to DrugPatentwatch for reference and further reading.